New York Times columnist David Brooks talks with Diane about what he sees happening inside Washington and around the country and why he thinks President Trump represents the wrong answer to the right question.
The Vioxx recall is just the latest of several episodes this year that have prompted criticism of the FDA and Senate hearings. A panel talks about the drug approval process, post-marketing safety surveillance, and how the agency’s work affects Americans’ health and safety.
- Dr. Jerry Avorn author of "Powerful Medicines," professor of medicine at Harvard Medical School, and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital in Boston
- Sen. Charles Grassley (R-Iowa), ranking member of the Senate Finance Committee
- Marc Kaufman reporter on the national desk of "The Washington Post"
- Alan Goldhammer, PhD associate vice president for regulatory affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA)
- Dr. Sandra Kweder deputy director of the FDA's Office of New Drugs
Most Recent Shows
Diane speaks with Dr. Roger Kligler who is living with advanced stage cancer on why he's suing the state of Massachusetts for the 'Right to Die' and with Dr. Jessica Zitter, and intensive care and palliative care specialist on why better communication is so needed between doctors and patients facing end-of-life issues.
Glenn Thrush, White House correspondent for the New York Times, describes operations inside the Trump White House, and science writer Sharon Begley explains why compulsions can useful in times of anxiety.
President Trump announces his nominee for the Supreme Court, legal battles ramp up in opposition to the Trump's executive order on immigration restrictions,and some in Congress vow to resist: Three political experts speculate on the future of our three branches of government and their respective powers in the Trump administration.